Mast Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1995-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://masttherapeutics.com
Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer
- Conditions
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02646358
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
Evaluation of Vepoloxamer in Chronic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02596477
- Locations
- 🇦🇺
Research Center, Melbourne, Victoria, Australia
Evaluation of Repeat Administration of Purified Poloxamer 188
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02449616
- Locations
- 🇺🇸
T. C. Thompson Children's Hospital, Chattanooga, Tennessee, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸Joe Dimaggio Children's Hospital, Hollywood, Florida, United States
Evaluation of MST-188 in Acute Lower Limb Ischemia
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02093468
- Locations
- 🇺🇸
Research Center, Cleveland, Ohio, United States
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT01790087
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
- Conditions
- Interventions
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 388
- Registration Number
- NCT01737814
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital at the University of Illinois, Chicago, Illinois, United States
A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2009-05-28
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00663481
- Locations
- 🇺🇸
Parexel International - Baltimore CPRU, Baltimore, Maryland, United States
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2009-05-28
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00664170
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇪🇪Tallinn Cancer Clinic, Tallinn, Estonia
🇺🇸Signal Point Hematology/Oncology Inc., Middletown, Ohio, United States
5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients
- Conditions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00434369
- Locations
- 🇷🇺
Clinical Research Site in, Kazan, Russian Federation
🇪🇸Clinical Investigative Site, Valencia, Spain
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
- Conditions
- First Posted Date
- 2007-02-08
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00432562
- Locations
- 🇦🇷
Clinical Investigative Site, Tucuman, Argentina